Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitomycin C vs mitomycin C plus locoregional hyperthermia in intermediate-risk non-muscle invasive bladder cancer
NL-OMON21384Phase 3Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mitomycin c in non-muscle-invasive bladder cancer (NMIBC) and transitional cell carcinoma of the bladder (TCC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Recurrence-free survival. Started Sep 2015; status: active, not recruiting.
02
Drugs
mitomycin c
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)
Beyond the preview
Go deeper on NL-OMON21384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21384.